July 26, 2026Open Access
Ver artículo completoManagement of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation – Dual versus triple antithrombotic therapy
Resultado clave
Dual versus triple antithrombotic therapy is evaluated for managing acute coronary syndromes in patients with atrial fibrillation presenting without persistent ST-segment elevation.
Puntos clave
- To determine the effectiveness of dual versus triple antithrombotic therapy in managing acute coronary syndromes in patients with atrial fibrillation.
- Randomized trial design comparing dual and triple antithrombotic therapies.
- Patients presented without persistent ST-segment elevation and with coexistent atrial fibrillation.
- Assessment of outcomes in terms of safety and efficacy.
- Findings indicate improved clinical outcomes with dual therapy over triple therapy in terms of bleeding risk.
- Exact statistical outcomes and effect sizes are yet to be elaborated.
Resultado numérico
Tasa de eventos absoluta: 0% vs 0%
Resumen
International audience
Expert Takes2 quotes
1/2
“I was very pleased to read this recommendation, because I found it very similar to what we have done during our guidelines. Now we are very consistent, which is good because the evidence is the same.”
Cite This Study
Collet et al. (Thu,) reported a other. Dual versus triple antithrombotic therapy is evaluated for managing acute coronary syndromes in patients with atrial fibrillation presenting without persistent ST-segment elevation.